Randomized Comparison of Intermediate-Dose Cytarabine Plus Mitoxantrone (IMA) Versus Standard-Dose Cytarabine Plus Daunorubicin (DA) for Induction Therapy in AML Patients >60 Years. Results from the SAL 60+ Trial
Christoph Röllig(University Hospital Carl Gustav Carus), Ulrich S. Schuler(University Hospital Carl Gustav Carus), Sebastian Fetscher(University Medical Center Freiburg), Christian Thiede(University Hospital Carl Gustav Carus), Michael Krämer(University Hospital Carl Gustav Carus), Maria Gabrecht(University Hospital Leipzig), Frank Heits(Agaplesion Diakonieklinikum Rotenburg), Hermann Einsele(Universitätsklinikum Würzburg), Gerhard Ehninger(University Hospital Carl Gustav Carus), Luisa Mantovani‐Löffler, Markus Schaich(Rems-Murr-Klinikum), Wolfgang E. Berdel(University Hospital Münster), Martin Bornhäuser(Technische Universität Dresden), Johannes Kullmer(DIAKO), Regina Herbst(Klinikum Chemnitz), Hartmut Link(Medizinische Hochschule Hannover), Mathias Hänel(Klinikum Chemnitz), Ulrich Krümpelmann(Klinikum Bielefeld), Ulrich Kaiser(University of Applied Sciences Landshut), Uwe Platzbecker(National Center for Tumor Diseases), Hubert Serve(Goethe University Frankfurt), Brigitte Mohr(Klinik und Poliklinik für Psychotherapie und Psychosomatik), Kerstin Schäfer‐Eckart(Nuremberg Hospital), Barbara Ritter(Klinikum Kassel), Alwin Krämer(Heidelberg University), Norbert Schmitz(University Hospital Münster), Thomas J. Neuhaus(University of Zurich), Johannes Schetelig(University Hospital Carl Gustav Carus)
Cited by 4
Related Papers
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k